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Due to the rapid emergence of multi-resistant bacterial strains in recent decades, the
commercially available effective antibiotics are becoming increasingly limited. On the
other hand, widespread antimicrobial peptides (AMPs) such as the lantibiotic nisin has
been used worldwide for more than 40 years without the appearance of significant
bacterial resistance. Lantibiotics are ribosomally synthesized antimicrobials generated
by posttranslational modifications. Their biotechnological production is of particular
interest to redesign natural scaffolds improving their pharmaceutical properties, which
has great potential for therapeutic use in human medicine and other areas. However,
conventional protein engineering methods are limited to 20 canonical amino acids
prescribed by the genetic code. Therefore, the expansion of the genetic code as
the most advanced approach in Synthetic Biology allows the addition of new amino
acid building blocks (non-canonical amino acids, ncAAs) during protein translation. We
now have solid proof-of-principle evidence that bioexpression with these novel building
blocks enabled lantibiotics with chemical properties transcending those produced by
natural evolution. The unique scaffolds with novel structural and functional properties
are the result of this bioengineering. Here we will critically examine and evaluate the
use of the expanded genetic code and its alternatives in lantibiotics research over the
last 7 years. We anticipate that Synthetic Biology, using engineered lantibiotics and
even more complex scaffolds will be a promising tool to address an urgent problem
of antibiotic resistance, especially in a class of multi-drug resistant microbes known
as superbugs.
Keywords: genetic code expansion, chemoselectivity, RiPPs, lantibiotics, non-canonical amino acids, nisin,
superbugs, synthetic biology
ANTIMICROBIAL RESISTANCE AND SUPERBUGS
The use of antibiotics has enormously empowered modern medicine to save human lives and
perform medical and surgical treatments under safe conditions (Aslam et al., 2018). In addition,
treatment with antibiotics is one of the most important approaches to combat or prevent bacterial
infections in animal populations and in the food industry. The widespread use of antibiotics
began already during the Second World War, and Alexander Fleming himself was one of the
first to recognize how improper use of these compounds could lead to antibiotic-resistant bacteria
(Fleming, 1945). The habitats of our planet are saturated with various toxic substances, especially
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those of anthropogenic origin, which has contributed
significantly to the selection of resistant strains (Davies and
Davies, 2010). Indeed, the excessive use of antibiotics in
agriculture, in the environment, animals (food, pets, aquatic
fauna) and human medicine, and their release into the
environment through fertilizer/feces is the most plausible cause
of antimicrobial resistance (AMR) (Manyi-Loh et al., 2018).
The emergence of pathogens causing enhanced morbidity
and mortality due to modifications in various physiological and
biochemical mechanisms has led to multi-resistant microbes
known also as “superbugs” (Coast et al., 1996). For example, in
different microbial strains, resistance has emerged at multiple
levels of defense, starting from the entry level (through the
limitation of drug permeability and the existence of efflux pumps)
to the degradation of the antibiotics via their modification
or hydrolysis. Next, lateral gene transfer, alteration of binding
through target modification and escape of toxicity through
bypass reactions and metabolic shunts were (among others)
documented as mechanisms for the development of single or
multiple resistances (Yelin and Kishony, 2018). To sum up, due
to the rapid appearance of multi-drug resistant bacterial strains in
last few decades, the use of commercially available antibiotics has
become increasingly limited. A promising alternative could be the
use of antimicrobial peptides (AMPs) with many variants already
in clinical trials (Table 1). Many bioactive peptides produced
from various microorganisms (e.g., actinobacteria, cyanobacteria,
bacilli, fungi) have a potential to serve as drugs against numerous
pathogens (Greber and Dawgul, 2017; Ongey et al., 2017;
Koo and Seo, 2019).
ANTIMICROBIAL PEPTIDES
Antimicrobial peptides (AMPs) also known as host defence
peptides are one of the most versatile natural products which
represent alternatives to traditional antibiotics. In fact, AMPs are
a special group of natural products that occur in almost every
form of life, namely microorganisms, plants, and animals as an
innate immune response (Ageitos et al., 2017). They can be used
to treat various infections caused by pathogenic species with
better efficacy, selectivity and specificity. Structurally, AMPs are
versatile peptides with diverse lengths of almost always less than
80 amino acids in a linear or cyclic structure with a broad set
of biotechnological applications, e.g., antibiotics, and inhibitors
(Oliva et al., 2018).
Antimicrobial peptides can be classified on the basis
of their parent organism, their biosynthetic production
pathway (e.g., ribosomal or non-ribosomal origin), their
activity spectrum, and their structural features (usually based
on predominant secondary structure) or physicochemical
properties (e.g., cationic/anionic, hydrophilic/hydrophobic
etc.). They are structurally divided into five main classes,
including (i) linear α-helical peptides, (ii) β–sheet-containing
peptides, (iii) peptides with α- and β-structural elements,
and (iv) extended or non-αβ secondary structure elements
(e.g., polyproline helices) (Wang, 2015). Furthermore, they
also occur in the form of (v) cyclic peptides and other
topologically complex scaffolds, which are often ribosomally
produced and post-translationally modified peptides (RiPPs)
(Koehbach and Craik, 2019). Another classification system
divides AMPs into natural, encrypted (Brand et al., 2012),
and designed AMPs which are a product of specific genes
or as part of larger proteins released after proteolysis, and
the artificial ones developed by rational design techniques,
respectively (Cardoso et al., 2016; Porto et al., 2017). Figure 1
summarizes the various methods of AMPs classification in the
current literature.
Three models (Carpet/Aggregation/Detergent-like model,
Toroidal model, and Barrel-Stave model) have been proposed
to explain the mechanism of action of AMPs for the ability to
kill bacterial pathogens via membrane permeability (Figure 2).
In all these models AMPs act in two sequential steps (Brogden,
2005). In the first step, electrostatic interactions are established
between the positively charged amino acids in CAMPs with the
negatively charged membrane surface, such as the pyrophosphate
group of lipid-II in the cell membrane of microorganism or
phosphatidylethanolamines in the outer leaflet of the target
cell membrane. In the second step, the formation of pores
within the membrane causes the bilayer to break open,
which leads to extensive leakages and finally to cell death,
particularly in Gram-positive bacteria. Detailed descriptions of
detergent-like effects of amphipathic cationic AMPs and other
models of membrane disruption by AMPs are described in
great detail in the contemporary literature (see e.g., Zweytick
et al., 2006). Achievable chemical diversity and variability in
the production of peptides together with almost unlimited
sequence space for matching their physicochemical properties
and generating broad-spectrum antimicrobial activity make them
a valid alternative to antibiotics in the effort to combat multi-
drug resistant strains and save human lives in the face of future
epidemic and other challenges (Ageitos et al., 2017). Nevertheless,
several obstacles remain to be overcome in order to develop
AMPs for medical use, such as toxicity, stability, and even
bacterial resistance. Another obstacle is the lack of standard
experimental procedures for quantifying AMP activity and we
still do not have a clear picture of several AMP’s mechanisms of
action (Torres et al., 2019).
LANTHIPEPTIDES ARE RIBOSOMALLY
PRODUCED AND
POST-TRANSLATIONALLY MODIFIED
PEPTIDES (RIPPS)
RiPPs are an important class of AMPs, ribosomally synthesized
and post-translationally modified bio-active peptides in all
three domains of life and show great structural diversity. They
are subdivided into more than twenty well-known categories
including lanthipeptides, linaridins, proteusins, linear azol(in)e-
containing peptides (LAPs), cyanobactins, thiopeptides,
bottromycins, microcins, lasso peptides, microviridins,
sactipeptides, bacterial head-to-tail cyclized peptides, amatoxins
and phallotoxins, cyclotides, orbitides, conopeptides, glycocins,
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TABLE 1 | List of selected promising AMPs in preclinical or clinical trials.
AMP type Mechanism Application Trial phase References
Mutacin 1140 Lantibiotic Lipid-II binding Bacterial infection Pre-clinical Kers et al., 2018
NVB333 Lantibiotic Lipid II binding Bronchoalveolar
infection therapy
Pre-clinical Boakes et al., 2016
NVB302 Lantibiotic Lipid-II binding Clostridioides
difficile infections
Phase I Boakes and
Dawson, 2014
Duramycin Lantibiotic Binding to
Phosphatidylethanolamine
Cystic fibrosis,
Inhibit cell entry of
viruses
Phase II Huo et al., 2017
DPK-060 Kininogen-derived
peptide
Membrane
targeting
Atopic dermatitis Phase II Håkansson et al.,
2019
OP−145 LL−37 derivative Bacterial
membrane
dissolution
Chronic leg ulcers,
Wound healing
effect
Phase II Ming and Huang,
2017
D2A21 Synthetic Unknown Burn wound
infections
Phase III Chalekson et al.,
2002
SGX942 (Dusquetide) Synthetic Innate defense
regulator
Oral Mucositis Phase III Kudrimoti et al.,
2017
PXL01 Lactoferrin analog Repressing
secretion of
cytokines
Post-surgical
adhesions
Phase III Nilsson et al., 2009
Omiganan (CLS001) Indolicidin
derivative
Affect the
cytoplasmic
membranes of
bacteria
Catheter-related
infections
Phase III Feng et al., 2015
POL 7080 (RG7929) Protegrin analog Inhibiting LptD Septicemia, lung
and thigh models
Phase III Srinivas et al., 2010
FIGURE 1 | Classification of AMPs on the basis of various criteria. (A) Based on gene encoding pattern (Data-mining strategy). (B) Significant cellular or
thermodynamic criteria. (C) Subdivision of positively charged (cationic) AMPs. RiPPs are structurally diverse but exclusively synthesized by ribosomes. This figure
was compiled from a variety of sources (Porto et al., 2017; Koehbach and Craik, 2019).
autoinducing peptides (AIPs), pyrroloquinoline quinone (PQQ),
pantocin A and thyroid hormones, etc. (Arnison et al., 2013).
In this context, lanthipeptides are classified as one the
largest group of RiPPs assigned in class I of bacterial-origin
AMPs (bacteriocins). They are transformed into a mature
active form by special post-translational modifications (PTMs)
carried out by a battery of dedicated enzymes. Class I of
bacteriocins include lantibiotics, linear azol(in)e-containing
peptides (LAPs), thiopeptides, bottromycins, glycocins, lasso
peptides, head-to-tail cyclized bacteriocins, sactibiotics, and
lipolanthines (Acedo et al., 2018). Bacterial lanthipeptides
exhibit outstanding properties such as conformational rigidity,
increased metabolic and chemical stability as well as intense cell
permeability that distinguish them from other heat-stable (class-
II) and thermo-labile (class-III) bacteriocins (Alvarez-Sieiro et al.,
2016). In addition to the four earlier types of lanthipeptides
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FIGURE 2 | Configuration of the target membrane environment leading to the initial electrostatic and hydrophobic interactions of the AMPs on the bacterial
membrane. Initial molecular event of the effect of the AMPs leads to the different scenarios that can be described using transmembrane pore and non-pore models.
The carpet model, without pores: AMPs aggregate on the bilayer surface resulting in detergent-like disintegration, whereby the membrane is fragmented into
micelles. Conversely, in the "barrel stave" model, membrane pores are formed by interactions between the hydrophobic surface of the pore and the acyl chains of
the lipid core of the bilayer. The "toroidal pore" model (wormhole) combines the effects described by both the barrel stave and the carpet model. For a more
comprehensive overview see Sun et al. (2018). However, it should be noted that the different mechanisms of AMPs action presented here do not cover the entire
range of ribosomally produced and post-translationally modified peptides (RiPPs, vide infra), since not all members of this group damage membranes or form pores,
but have different targets and mechanisms of action.
classified based on the biosynthetic mechanisms involved in
their structural maturation, the recently discovered modified
peptides, including Cocaoidin and Lexapeptide, exhibited novel
modification features such as different biosynthetic gene clusters
and have been introduced as class V lanthipeptides (Ortiz-López
et al., 2020; Xu et al., 2020).
In general, lantibiotics show an efficient ability to kill
Gram-positive bacteria and are particularly important for
those that exhibit drug resistance such as methicillin-
resistant Staphylococcus aureus (MRSA), Streptococcus
pneumoniae (MRSP), vancomycin intermediate S. aureus
(VISA), vancomycin-resistant enterococci (VRE), Clostridioides
difficile, etc. Instability and/or insolubility at physiological pH,
susceptibility to proteolytic degradation, and a low level of their
production are features that mainly limit the use of lantibiotics in
the clinic. It should also be noted that the antimicrobial activity
of lanthipeptides is well understood and characterized in some
RiPPs such as nisin (achieved by lipid-II binding) (Kuipers et al.,
1996). Later, the lipid-II binding activity of some lantibiotics
was also demonstrated (Wiedemann et al., 2001; Breukink and
de Kruijff, 2006), although in some of them the mechanisms
of action have yet to be clarified. Nonetheless, low cytotoxicity
of lantibiotics to human cells due to the absence of their main
target lipid II or negative net charge in eukaryotic membranes
(Lagedroste et al., 2019) along with a few examples of naturally
occurring resistance (Draper et al., 2015; Khosa et al., 2016a,b;
Clemens et al., 2018) make lantibiotics excellent lead compounds
for development of new therapeutic options.
THE FEASIBILITY OF GENETIC
ENGINEERING TO PRODUCE MORE
POTENT LANTIBIOTICS
RiPPs Recombinant Expression for
Classical Engineering—Nisin as an
Example
A wide range of technologies are at our disposal for producing
a peptide such as chemical synthesis, recombinant DNA
technologies, and in vitro translation systems. The choice
of a strategy for gene-encoded peptide production is largely
determined by their size and chemical complexity. Peptides
with sophisticated PTMs-generated structures such as RiPPs are
preferably produced biosynthetically using host expression cells.
Host cells with installed and functional PTM enzymes should be
able to express RiPPs in an intact active form with distinctive
architecture dominated by lanthionine bridges. In this context,
the absence of a widely used large-scale production platform for
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lantibiotics with consistent quality is one of the main drawbacks
of their therapeutic application.
There are generally two options for recombinant expression
of lantibiotics, homologous or heterologous expression systems.
Homologous expression strategies have limited use in particular
due to the difficulty of cultivating the original producers (Maffioli
et al., 2015; Mohr et al., 2015) and/or the difficulty of lantibiotics
expression induction under laboratory conditions (Wescombe
et al., 2011; Garg et al., 2012). Conversely, heterologous
biosynthesis with host cells such as Lactococcus lactis, Bacillus
subtilis, Bacillus cereus, and E. coli are normally preferred
and, in many cases, well established. So far, several genetically
manipulatable Streptomyces strains, including Streptomyces
lividans (Ahmed et al., 2020), S. albus (Myronovskyi et al.,
2018), S. coelicolor M145 (Gomez-Escribano and Bibb, 2011),
S. venezuelae ATCC 15439 (Kim et al., 2015), S. avermitilis
(Komatsu et al., 2010) have been reported to synthesize
natural products from genetically engineered biosynthetic
gene clusters. However, Escherichia coli is still the most
common and attractive option. A list of successful examples
of recombinant expression of different RiPPs families in
heterologous hosts such as E. coli and Streptomyces strains
were recently compiled by Zhang and colleagues (Zhang et al.,
2018). Heterologous production of lantibiotics is generally
conducted as inactive form of the antimicrobial peptide (pre-
lantibiotic) to prevent any detrimental effects on host cell
growth and viability.
In addition, there is great interest to express lantibiotics
in microbial host that should facilitate a straightforward
and efficient engineering (Kuipers et al., 1996). Numerous
conventional protein engineering approaches such as
site-directed mutagenesis, directed evolution and various
computational tools aid synthetic biologists and biochemists
to selectively diversify the properties of expressed therapeutic
peptides. These include manipulations of thermodynamic
stability, increased bioavailability, reduced aggregation or
enhanced specificity and proteolytic stability (Adhikari et al.,
2019). In addition, the implementation of in vitro and in vivo
approaches in combination with genome mining data and high-
throughput screening strategies has opened up unprecedented
opportunities to modify and even improve antimicrobial
activity, manipulate the physicochemical properties and
widening of the antibacterial spectrum in the production of
lantibiotics (Field et al., 2015). Recently an attempt to design
and biosynthesize a two-lipid II binding motifs-containing
lantibiotic, called TL19, is the latest example showing 64-
fold stronger activity against Enterococcus faecium than nisin
(Zhao et al., 2020).
The potential of classical protein engineering in complex
RiPPs is perhaps best illustrated by recombinant nisin, well
known for its broad-spectrum antibacterial activity produced
in certain strains of L. lactis (Lubelski et al., 2008). Nisin
as the most widely used lantibiotic in the food industry
over the past 50 years has undergone various methods of
bioengineering with an aim to improving its function and/or
physicochemical features (Shin et al., 2016). To expand the
scope of its activity, several bioengineered variants of nisin have
been generated by site-directed mutagenesis and by classical
chemical modifications (Ross et al., 2012), including in vitro
chemical synthesis (Knerr and van der Donk, 2012; Koopmans
et al., 2015). For example, the use of the saturation mutagenesis
approach has led to the production of nisin S29 derivatives with
increased activity against a number of Gram-positive antibiotic-
resistant pathogens. In addition, the increased antimicrobial
activity was generated in comparison to the wild type nisin A
when tested against Gram-negative food-borne pathogens (Field
et al., 2012). Moreover, recombinant production of the nisin Z
mutants N20K, M21K, N27K, H31K improved peptide solubility
at alkaline pH (Rollema et al., 1995). Next, residue alterations
at distinct locations enabled the improvement of antimicrobial
activity (Islam et al., 2009; Healy et al., 2013; Geng and Smith,
2018), the enhancement of diffusion through complex polymers
(Rouse et al., 2012), and widening effect on some Gram-negative
bacteria (Field et al., 2012).
Studies on the effects of the hinge region (NMK) length
between rings C and D on antimicrobial activity and host
specificity of nisin was also performed (Zhou et al., 2015).
Although most variants with shorter or larger hinge length are
less active than the wild type, some variants (+2, +1, −1,
−2) exhibited higher antimicrobial activity than the wild type
nisin A in agar-well-diffusion assays against L. lactis MG1363,
Listeria monocytogenes, Enterococcus faecalis VE14089, Bacillus
sporothermodurans IC4, and Bacillus cereus 4153. In addition,
an extended nisin A variant of the hinge region (20NMKIV24)
has been introduced, bypassing the human pathogen’s lantibiotic
resistance while showing a slight decrease in antimicrobial
activity (Zaschke-Kriesche et al., 2019). In this context, Figure 3
represents different variants of nisin produced by classical protein
engineering together with a graphical representation of the
mechanism of action of this bioactive peptide.
However, the expression of lantibiotics in popular prokaryotic
hosts like E. coli is challenging as these bacteria have no enzymes
to perform suitable PTMs to convert pro-peptide into a mature
bioactive peptide. Therefore, their recombinant expression has
to be coupled with the co-expression of active PTM biosynthetic
gene clusters either in vitro or in vivo. These strategies are not
in the focus of our study and interested readers are directed to
numerous studies and reviews dedicated to this topic (Zhang
et al., 2018; Myronovskyi and Luzhetskyy, 2019). We are mainly
concerned with the in vivo design strategies that focus to expand
the functional scope of AMPs from ribosomal templates beyond
the classical protein engineering approaches.
Beyond Classical Protein Engineering:
Expanding the Scope of Protein
Translation
It was argued that chemical and functional diversity delivered by
PTMs in AMPs such as lantibiotics can be further supplemented
or even expanded by the co-translational insertion of non-
canonical amino acids (ncAAs) (Budisa, 2013). Indeed, a limited
and conservative set of 20 canonical amino acids used by
ribosomes to encode polypeptides in nature usually does not
cover enough chemical space required to substantially expand
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FIGURE 3 | Nisin is one of the best-studied ribosomally synthesized, pore-forming, cationic, antimicrobial peptides. (A) Sequence comparison of three nisin
variants from L. lactis and marking the important regions of nisin targeted for bioengineering by classical molecular biology approaches (Chatterjee et al., 2005);
(B) two-steps mode of action of nisin.
their functional and structural diversity. In nature, this is
normally achieved by site-selective PTMs that create special
non-canonical amino acid side chains such as dehydroalanine
(Dha) and dehydrobutyrine (Dhb) in lantibiotics (Figure 3).
To directly mimic these and similar PTMs, chemists used,
e.g., rhodium-catalyzed arylations (Key and Miller, 2017),
P450-catalyzed cyclopropanations (Gober et al., 2017), and
photocatalytic activation (de Bruijn and Roelfes, 2018) in
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FIGURE 4 | The radial arrangement of the standard genetic code in RNA format (A) with the side chains of 20 canonical amino acids (cAA). The standard amino acid
repertoire of the genetic code can be modified or expanded (B) by non-canonical amino acids (ncAAs). By reprogramming protein translation, the ncAAs can be
incorporated into recombinant proteins using in vivo and in vitro methods. These insertions offer useful modifications that can be made to the protein main chain
(backbone) and the amino acid side chains (aliphatic or aromatic). Modified backbones and side chains often have unique physicochemical properties with the
potential to dramatically expand the chemical and functional space of ribosomally synthesized peptides and proteins.
thiopeptides, as well as metalloporphyrin-catalyzed alkylation of
methionine in nisin (Maaskant and Roelfes, 2019) as attempts
to obtaining novel AMPs with improved properties and/or
activities. However, it is difficult to mimic PTM machinery
chemically, whereas classical peptide synthetic protocols such
as solid-phase peptide synthesis (SPPS) could not cover the
chemical complexity of these natural products.
Therefore, the use of recombinant DNA technology that
operates with heterologous expression of biosynthetic gene
clusters and enriched with reprogrammed protein translation
(Figure 4) can provide a reasonable solution to the above-
mentioned problems (Hoesl and Budisa, 2012). It enables
specific insertion of the biological, chemical, and physical
properties delivered by ncAAs that can be accurately defined
by the chemist at the bench. Cells equipped with various
bioorthogonal chemistries have the potential to perform catalytic
transformations that are not found in biology, including the
creation of new metabolic and informational pathways (Devaraj,
2018). These modifications can also serve as redox sensors,
spectroscopic markers (e.g., spin-labeling) or sensors of protein-
ligand interactions. Metal-binding amino acids could lead to new
structural, catalytic, or regulatory elements in proteins, while
diazirines allow site-specific photo-crosslinking of the target
protein to its substrate. Photoactive and photo-isomerizable
ncAAs with novel photo-physical properties such as azobenzene
side chains can be used to photo-regulate protein activity.
Similarly, photocaged ncAAs can be activated by light to
turn on enzymatic activity spatiotemporally (for review see
Young and Schultz, 2010).
Directed evolution of aminoacyl-tRNA synthase (aaRS) plays
a key role in the generation of such molecular tools. Desired
ncAAs can be incorporated in a site-directed manner by
reading in-frame stop codons, usually amber stop codons
(UAG) with a suitable orthogonal pair (o-pair). Such a
pair consists of an aaRS enzyme to activate the ncAA and
its associated orthogonal tRNA (vide infra). However, the
transition to recombinant production with such a possibility
by using heterologous expression hosts is not trivial. For
that reason, the residue-specific replacement of a particular
amino acid at all positions in a protein sequence (known as
selective pressure incorporation, vide infra) is a reasonable
alternative as it does not require o-pairs (Budisa, 2004).
Finally, the capacity of ncAAs incorporation should not
interfere with the sequence of posttranslational modifications
leading to the formation of lantibiotics and the restoration of
their bioactivity.
With such systems in hands we would have very sophisticated
tools to rationally engineer RiPPs scaffolds as now they can
be redesigned by reprogrammed protein translation which
utilize various ncAAs. This approach would have many
advantages over the above discussed classical chemical or
recombinant approaches as it enables: (i) genetic encoding of
desired ncAAs and its sequence positioning; (ii) recombinant
production under mild conditions at room temperature and
atmospheric pressure; (iii) the targeted functionalization
(e.g., various site-directed bioconjugations, light induced
cross-linking, metal or cofactor binding, fluorophore or
pharmacophore attachment, adhesiveness, etc.) (Cropp and
Schultz, 2004). Crucial requirements to expand the scope of
protein synthesis with ncAAs should be cellular uptake, their
intracellular metabolic stability and translational activity (i.e.,
incorporation). Finally, it is necessary to reallocate (reassign)
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FIGURE 5 | Expansion of scope of the nisin A biosynthesis by ncAAs. The biosynthetic production of active nisin involves the expression of peptide precursors with
20 canonical amino acids as standard building blocks, followed by posttranslational modifications (PTMs). The active form of natural nisin is characterized by the
presence of unusual posttranslationally introduced bridge structures known as lanthionines (depicted in orange). It is generally expected that the incorporation of
ncAAs (i.e., co-translational modifications) along with post-synthetic modification options (e.g., click chemistry) will create additional functional and structural levels of
RiPPs diversification. For example, new variants with improved properties such as stability, specificity, bioavailability, action spectrum and half-life could be created.
This is particularly important in view of the fact that nisin is highly effective against a number of human clinical pathogens, including many multi-drug resistant strains
(Piper et al., 2009). In recent years it has been clearly demonstrated that several variants of nisin increase activity or stability in different experimental setups (reviewed
in Field et al., 2015).
coding triplets (codons) in the genetic code to insert ncAAs in
target protein/peptide sequences.
RECOMBINANT LANTHIPEPTIDES
PRODUCED BY INCORPORATING
NON-CANONICAL AMINO ACIDS
Reprogrammed Protein Translation for
Chemoselective Labeling of Lantibiotics
The bioexpression of lantibiotics is not fully comparable to
the routine recombinant expression of soluble proteins because
these polypeptides contain precursor (consisting of leader and
core peptide) and recognition sequences. The core peptide is
modified by post-translational modification (PTM) enzymes
and upon proteolysis and export, transformed into a complex
natural product. Unlike non-ribosomal natural products, native
RiPPs cannot explore amino acids beyond the canonical 20
proteinogenic amino acids in the synthesis of precursor peptides,
limiting their structural diversity at this level of ribosomal
synthesis. On the other hand, from a biotechnological point of
view, the great advantage of the ribosomal synthesis (coupled
efficiently with PTMs) of bioactive compounds would be the
possibility of achieving high chemical diversity at low genetic
cost and to avoid supply of expensive precursors. The drawback
that many unusual building blocks (found in non-ribosomal
synthesis) are absent in RiPPs can be efficiently circumvented
by genetic code expansion (GCE). The insertion of ncAAs
(in different combinations of their numbers and chemistry)
into growing peptide represents a novel level of chemical
diversification of these sequences (Figure 5). Incorporated ncAAs
can either directly interfere with PTMs or occupy sequence
positions not affected by the PTM machineries. This provides
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suitable bio-orthogonal reactive groups (‘handles’) amenable for
various chemoselective ligand couplings. In addition, both site-
and residue-specific incorporation techniques generally allow for
fine chemical manipulations of the amino acid side chains, e.g.,
of Pro, Trp, Tyr, Met and to visualize them in spectroscopic
recordings (Baumann et al., 2018).
Non-canonical amino acids equipped with specific chemical
groups (azides, olefins, ketones and aldehydes, loaded and
unloaded alkynes, halogens, oximes, hydrazones, boronic acid
esters and acids, etc.) give polypeptide sequences a unique
reactivity and chemoselectivity that allow easy and efficient
bioconjugations to a variety of ligands (Agostini et al., 2017).
The copper(I)-catalyzed Huisgen cycloaddition reaction between
azides and alkynes (also known as “click chemistry”) is
widely used to functionalize labeled proteins since it takes
place under physiological conditions allowing full retention of
the protein structure (Kolb et al., 2001). For example, click
chemistry proved to be efficient in producing nisin-peptoid
hybrids for therapeutic use (Bolt et al., 2018). Further, in vitro
metathesis reaction confirmed the capability of the variants for
post-biosynthetic modifications such as conjugation reactions
with ligands, labels, or tags using bio-orthogonal chemistry.
Other alternatives include recently developed very efficient
chemoselective methods; mainly copper-click, photoclick, and
catalyzed oxime/hydrazone chemistries (Devaraj, 2018). This
methodology could provide the RiPPs derivatives with an
increase in chemical diversity such as enhanced proteolytic
resistance, or increased bioavailability. Finally, bioexpression
with various ncAAs combined with the possibilities for further
chemical processing of RiPPs after maturation (i.e., semi-
synthesis of mature products) makes the number of possible
chemical combinations in antibiotic design virtually limitless.
To gain access to such a sophisticated chemistry in
recombinant proteins, the incorporation of suitable ncAAs must
be established in order to have possibilities for the site- or
residue-specific functionalization of e.g., bioorthogonal alkyne-
or azide-containing moieties. The simplest strategy for the in vivo
insertion of ncAAs is based on the use of auxotrophic microbial
systems and is known as selective pressure incorporation
(SPI) (Minks et al., 2000). This methodology also exploits
natural substrate tolerance (“substrate promiscuity”) of protein
translation machinery components toward ncAAs analogs. For
example, with a Met-auxotrophic E. coli strain in Met-depleted
medium, it was possible to express proteins in which methionine
was replaced by different medium-supplemented Met analogs
with a terminal azide or alkyne as a side chain (Figure 6).
The incorporation protocol typically requires the addition of the
ncAA analog in the growing medium, which is taken up by the
cell machinery and used in protein translation (Budisa, 2004).
Furthermore, the SPI is well known for higher translation yields
without the need for extensive host engineering.
The SPI method essentially requires a genetically and
metabolically stable auxotrophic expression host with ncAA
recognized and activated by endogenous translation apparatus.
Efficient and robust protein expression systems with controlled
fermentation and expression conditions usually yield target
proteins often similar to the wt-counterparts. This was
demonstrated in 2012, when the first application of the SPI
method for RiPPs was reported (Oldach et al., 2012). In
particular, the residue-specific incorporation of various Trp, Met,
and Pro analogs into the modular two-component lantibiotic
lichenicidin proved to be fully attainable (Figure 6). In this
system, the plasmid-encoded SPI-based expression of modular
propeptides is coupled with the expression of the fosmid-encoded
PTM machinery in the E. coli host cells. It has also been shown
that lichenicidin with the Met analog homopropragylglycine
(Hpg) can be post-synthetically functionalized by click chemistry
using azidofluorescein as a ligand.
However, the fundamental disadvantage of the SPI method is
that it allows residue-specific substitution of the canonical amino
acid of interest by isosteric analogs, uncontrolled substitutions
in the entire proteome, possibly endangering the heterologous
PTM machinery and thus damaging the host expression cell.
Furthermore, often in this approach the incorporation of ncAA
is achieved in a statistical manner, which leads to a heterogeneity
of the protein samples. This can be circumvented by using site-
directed incorporation methods (Figure 7). However, if a site-
directed ncAA incorporation is desired, the protein translation
must be orthogonalized. A specific position in the protein to be
labeled is mutated to the in-frame stop (usually amber) codon in
the target gene. An essential part of this approach is therefore the
introduction of in-frame stop codons (UAG) in target mRNAs
decoded by the ribosome. In-frame stop codon suppression (i.e.,
readthrough) is achieved via a specially designed suppressor
tRNA charged with ncAA (by a dedicated enzyme) and leads to
the ncAA incorporation in a site-specific manner. This expands
the amino acid repertoire of the genetic code and provides
a basis for the technology known as stop-codon suppression
(SCS) also as GCE. GCE generally requires the introduction
of orthogonal aminoacyl-tRNA synthetase:tRNA pairs (o-pairs)
into recombinant expression systems. Heterologous expression
systems operating with orthogonal pairs are also known as
orthogonal translation systems (OTS) in the literature. This
research area is very well covered by a number of recent reviews
(see, for example, Soye et al., 2015; Arranz-Gibert et al., 2018).
In orthogonal translation, usually a TAG (amber) stop
codon is assigned to the ncAA and the orthogonal tRNA
anticodon is mutated to CUA for position-specific incorporation.
Orthogonal pairs of archaeal origin can be into eubacterial
(such as E. coli) or eukaryotic hosts (such as Saccharomyces
cerevisiae) and used to affect orthogonal translation (Wang
et al., 2006). In particular, to engineer o-pairs, it is necessary
to redesign an existing aaRS to activate the desired new
ncAA substrate. Commonly used orthogonal pairs are based
on Methanocaldococcus jannaschii tyrosyl-tRNA synthetase
(MjTyrRS) and Methanosarcina mazei/barkeri pyrrolysyl-tRNA
synthetases (MmPylRS or MbPylRS). Compared to E. coli
or eukaryotic hosts they show a distant phylogeny (due
to their archaeal origin) that allows their implementation
as o-pairs (i.e., they do not show cross-reactivity with the
endogenous translational apparatus) (Budisa, 2006). Enzyme
variants are generated by mutagenesis of the plasmid library
and selected iterative positive/negative selection cycles (Bryson
et al., 2017). This technology enables the incorporation of
Frontiers in Microbiology | www.frontiersin.org 9 November 2020 | Volume 11 | Article 590522
fmicb-11-590522 November 1, 2020 Time: 18:44 # 10
Karbalaei-Heidari and Budisa Genetic Code Expansion and Multiresistance
FIGURE 6 | Incorporation of Met analogs into the one subunit of the two-component lantibiotic lichenicidin using the SPI method. Top left: Structures of methionine
and its analogs. Met, L-methionine; Aha, L-azidohomoalanine; Hpg, L-homopropargylglycine; Nle, L-norleucine and Eth, L-ethionine. These analogs were used to
individually replace Met residues in the precursor peptide of lichenicidin (bottom right), which was also analytically confirmed (bottom left). The substituted α-peptide
of lichenicidin underwent PTM-activity, whereby the linear precursor peptide was converted into a polycyclic form that exhibits antimicrobial activity when mixed with
the β-peptide (top right). For more details see Oldach et al. (2012). Most recently, Kuipers and co-workers have demonstrated the use of click chemistry in the
engineering of nisin by using SPI with the methionine analogs Hpg and Aha (Deng et al., 2020).
FIGURE 7 | Flow chart of the SPI and SCS methods. Both methods can be performed separately or combined in a single expression experiment (Hoesl and Budisa,
2011). Further details, advantages and disadvantages of both methods are described in the text.
ncAAs containing different chemical entities into protein, both
at one position (site-directed) and at several positions (multi-
site mode). Recently, we have developed a computer-aided
approach (Baumann et al., 2019) to create highly diversified
libraries of aminoacyl-tRNA synthetases (AARSs) and have
demonstrated the engineering of orthogonal translations with
up to 50-fold improved insertion efficiency. This was made
possible by creating much larger libraries (with > 109 clones).
In conventional directed evolution protocols, only about 107
clones are generated.
We and others have already applied and optimized orthogonal
pairs for site-specific incorporation of fluorinated amino acids
(Völler et al., 2015). Recently, we also have developed a novel
and highly efficient orthogonal tyrosyl-tRNA synthetase from
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Methanocaldococcus jannaschii (MjTyrRS) for photo-activatable
L-DOPA derivatives (Hauf et al., 2017). Similarly, we evolved a
novel pyrrolysyl-tRNA synthetase from Methanosarcina mazei
(MmPylRS), which is able to incorporate S-allylcysteine (Sac) in
response to amber stop codons (Exner et al., 2017). This Mm- or
Methanosarcina barkeri PylRS (MbPylRS) variants should be an
ideal starting enzyme for the evolution of enzyme mutants with
high specificity for smaller substrates. These and other advances
in the field are recently summarized in a series of specific reviews
(Arranz-Gibert et al., 2019; Budisa and Schneider, 2019) and
highlights (Mayer, 2019; Yanagisawa et al., 2019).
Without a doubt, GCE will soon become a groundbreaking
technology that will allow the catalysis of reactions that are not
possible with canonical amino acids alone. More than 200 distinct
ncAAs have been incorporated into various peptides and proteins
so far (Vargas-Rodriguez et al., 2018). This technology has
already yielded new-to-nature RiPPs and proteins in general with
improved or novel physicochemical and biological properties
which enabled the study of the structure-function relationship
of proteins, imaging (Uttamapinant et al., 2015), probing
(Chatterjee et al., 2013) and even the development of new
therapeutics. Furthermore, it is possible to mask side chain
functionalities of amino acids of interest by replacing them
site-specifically with e.g., photo-caged ncAA. These masked
substrates can then be non-invasively unmasked by UV light
irradiation revealing critical functionalities (e.g., photo-caged
residues which are substrates for MjTyrRS and Mm or MbPylRS-
based orthogonal translation) (Drienovská and Roelfes, 2020).
For the incorporation of ncAAs into RiPPs, various methods
have been considered so far, ranging from in vitro synthesis
reactions to residue and site-specific in vivo incorporation
(Bartholomae et al., 2018). To maximize the yield and cost-
effective production of lantibiotics, the biological synthesis of
these compounds offers a viable alternative strategy with less
downstream processing.
GCE as a Technology for New-To-Nature
Lanthipeptides: Troubleshooting and
Some Insider Tips
The deeper understanding of the molecular mechanisms
behind the activities of AMPs, their selectivity and rational
manipulation requires the application of novel technologies of
peptide modifications. Incorporation of ncAAs is a particularly
promising tool, which is able to deliver new chemical functions
and specific probes into peptide structures. For example, Nagao
et al. reported the first example of heterologous expression of the
type II lantibiotic, nukacin ISK-1 in E. coli by co-expression of
NukA and the modification enzyme NukM (Nagao et al., 2005).
In the following years, this approach was increasingly replaced
by the insertion of different ncAAs that mimic different PTMs,
such as the photocrosslinker p-Benzoyl-L-Phe (pBpa) in protein
and proteome chemistry due to the orthogonal translation rapid
development using different vectors and expression systems in
E. coli (Miyazaki et al., 2018). In general, the ncAA-insertion
provides many advantageous properties when compared with
PTMs, such as functional diversity, probing and controllable
activity. In this context, Table 2 represents a list of the new-to-
nature RiPPs biosynthetically produced via GCE methodology.
We define lanthipeptides expressed recombinantly with
ncAAs as "new-to-nature" because they are endowed with
chemical functionalities that are normally a domain of
classical organic chemistry. Most of such genetically encoded
modifications introduced in proteins and peptides (in vivo and
in vitro) take place on amino acid side chains and very seldom
on protein backbones (like e.g., modified proline analogs; see
Figure 4; Larregola et al., 2012). For example, D-amino acids, β-,
or γ-amino acids, dipeptides and dipeptidomimetic analogs can
be inserted into target polypeptide sequences by using engineered
in vitro translation systems (Lee et al., 2019). Translation with
backbone modification is difficult because ribosomes are being
evolved to facilitate the polymerization of α-L-amino acids into
polypeptides. Since the majority of the canonical amino acids
can be considered to be derivatives of alanine (Kubyshkin and
Budisa, 2019), the ncAA insertions (via SCS) or substitutions
(via SPI) are mainly additions of new side-chain functionalities-
a sort of useful co-translational addition to existing PTMs that
should greatly expand the functional performance of modified
peptides and proteins.
The engineering of orthogonal aminoacyl-tRNA
synthetase/tRNA orthogonal pairs (o-pairs) for the site-
specific incorporation of ncAAs is undoubtedly an important
tool in protein and peptide design. However, it should be noted
that orthogonalization of protein translation is usually associated
with a significant decrease in system performance. Therefore,
bio-expressions with orthogonal pairs require that the desired
ncAA is available in large excess (Völler and Budisa, 2017). In
addition, o-pairs based on both MjTyrRS and Mm(Mb)PylRS
scaffolds can have advantages and disadvantages in different
environments. In bacterial host cells, MjTyrRS often show a
higher performance compared with PylRS-based systems (Rauch
et al., 2016). In general, orthogonal translation with PylRS-
derived o-pairs leads to lower yields of target protein, since
this enzyme generally has a low catalytic efficiency (Baumann
et al., 2016). While o-pairs based on MjTyrRS allow a higher
number of in-frame stop codons that can be suppressed, this is
not the case with orthogonal translation based on PylRS (Zhao
et al., 2018). Many strategies have been reported to alleviate
these limitations, including the computational redesign of both
enzymes as discussed elsewhere (Baumann et al., 2019).
The incorporation of ncAAs via SCS into proteins in
general and RiPPs in particular is usually associated with
reduced expression efficiency since the readthrough of stop
codons is context-dependent. In particular, the insertion of
in-frame stop codons in target sequences might generate so-
called “context effects” with the competition with ribosomal
release factors (RFs) for the readthrough (Plotkin and Kudla,
2011). Next, the insertion of a stop codon into a specific
sequence is often associated with a high level of interference
with natural mRNA folding (Gorochowski et al., 2015). This
requires the optimization of mRNA sequences by applying a
computer-aided design that should restore or even improve
the strength of binding site interaction within the ribosome
(Del Campo et al., 2015). For these reasons, “context effects”
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TABLE 2 | List of the new-to-nature RiPPs produced by genetic code expansion technology reported so far.
Type Source/Host New RiPPs Activity*or Peptide
yield (mg/L)
References
Prochlorisin A 3.2 Class II
lantibiotic
Prochlorococcus/
E. coli
F26-pBpa Equal Shi et al., 2011
Capistruin Lassopeptide Actinobacteria/
E. coli
I4- Alk 0.110 Al Toma et al.,
2015I4-Nbk 0.039
I4-BocK 0.110
I4-Ack 0.042
I4-Pck 0.041
A10- Alk 0.290
A10-Nbk 0.218
A10-BocK 0.435
A10-Ack 0.149
A10-Pck 0.143
G17-Alk 0.033
G17-Nbk < LoQ
G17-BocK 0.013
G17-Ack < LoQ
G17-Pck < LoQ
MccJ25 Lassopeptide E. coli/E. coli V6, I13- mBr-F Less Piscotta et al.,
2015F10, F19- mBr-F Equal
V6, I13- mNO2-F Less
F10, F19- mNO2-F Less
V6, I13- mCl-F Less
F10, F19- mCl-F Equal
V6, I13- mCF3-F Less
F10, F19- mCF3-F Less
Thiocilin Thiopeptide B. cereus/B.
cereus
T3, T4, V6, T8, T13-BocK Decreased Luo et al., 2016
T3, T4, V6, T8, T13- AlocK Decreased
T3, T4, V6, T8, T13- ProcK Decreased
Nisin A Class I
lantibiotic
L. lactis/E. coli S3 -Fluoro-pAcF 2.00 Zambaldo
et al., 2017T8- Fluoro-pAcF 1.50
T13- Fluoro-pAcF 3.00
Cinnamycin Class II Type B
lantibiotic
S. albus/S. albus R2-Alk Decreased Lopatniuk
et al., 2017F10-Alk Decreased
Nisin A Class I
lantibiotic
L. lactis/L. lactis
L. lactis/E. coli
I4-BocK Equal Bartholomae
et al., 2018K12-BocK Equal
I4-BocK
K12-BocK
Lacticin 481 Class II
lantibiotic
L. lactis/E. coli W19-o-Cl-F,
W19-m-Br-F,
W19-o-NO2-F,
F21-oNO2-F,
F23-o-Cl-F
Increased Kakkar et al.,
2018
W19, F21, F23- oBr-F W19,
F21, F23- oNO2-F W19, F21,
F23- mBr-F W19, F21, F23-
mCF3-F
Decreased
ND, not determined. *Antimicrobial activity in comparison to wild-type; < LoQ = below the limit of quantification. L. lactis, Lactococcus lactis; S. albus, Streptomyces albus;
pBpa, p-benzoyl-L-phenylalanine; Nbk, Nε-5-norbornene-2-yloxycarbonyl-L-lysine; Alk, Nε-Allocl-Lysine; Ack, Nε-2-azidoethyloxycarbonyl-L-lysine; Pck, Nε-2-propyn-
1-yloxycarbonyl-L-lysine; Bock, Nε-Boc-L-lysine; mBr-F, meta-Bromo-phenylalanine; mNO2-F, meta-Nitro-phenylalanine; mCl-F, meta-Chloro-phenylalanine; mCF3-F,
meta-trifluoromethyl-phenylalanine; AlocK, Ne-allyloxycarbonyl-L-lysine; ProcK, Ne-prop-2-ynyloxycarbonyl-L-lysine; pAcF, p-acetylphenylalanine.
during the incorporation of ncAA in target sequences were
investigated by randomly generating in-frame stop codons along
the gene sequence with different proteins (summarized in
Agostini et al., 2017).
The screening of an amber stop codon library with lantibiotic
genes to study site-specific ncAAs incorporation efficiency
could be of great importance to improve and enhance the
biosynthesis of RiPPs with ncAAs. For example, we and others
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recently established a reporter platform for SCS approach
using three expression vectors capable of independent control
of different groups of genes. Each sense codon in the core
peptide region of NisA was replaced by TAG (amber) codon
and screening of possibly suitable incorporation positions was
assessed upon incorporation of various analogs (Bartholomae
et al., 2018). Next, in addition to the feasibility of a position
to incorporate ncAAs, the admissibility of target genes that
can fold and modify is critical and must always be considered.
This is best illustrated by the report of Shi et al. (2011), in
which the orthogonal translation was performed with three
different types of bioactive peptides, prochlorosins from class II
lanthipeptides, two-component lantibiotic haloduracin and the
class I lantibiotic, nisin.
As discussed above, the residue-specific replacement of a
particular amino acid at all positions in a protein sequence
with ncAA (i.e., SPI method) proved to be a reasonable
alternative in some cases (Hoesl and Budisa, 2011). Moreover,
incorporation of three different tryptophan analogs (5-fluoroTrp,
5-hydroxyTrp, and 5-methylTrp) into different positions of
nisin (I1W, I4W, M17W, and V32W), which included the
overexpression of tryptophanyl-tRNA synthetase (TrpRS) in
L. lactis strain PA1002, showed a reasonable incorporation
efficiency and suitable production yield (Zhou et al., 2016).
However, in a comparative study between the efficiency of ncAA
incorporation in orthogonal translation and by SPI method into
the lasso peptide capistruin, the SCS approach showed higher
efficiency (Al Toma et al., 2015).
Practical Expression, Purification,
Monitoring Strategies, and Challenges
With Novel Lanthipeptides
After induction and expression of the target gene, various
conventional methods such as immobilized metal affinity
chromatography (IMAC) and in rare cases, additional
column chromatography were applied for the purification
purposes. Due to the lack of a cell wall-anchored protease
(NisP), and to avoid the requirement for immunity as
well as to achieve higher production yield in E. coli
(Montalbán-López et al., 2018), activation of the purified
pre-lantibiotics is usually done by using native proteases
or some commercial enzymes in vitro. To assess proper
maturation of the lantibiotics, MS-analyses and bioactivity
assays have been employed. In addition, RP-HPLC is one
of the most convenient methods used for the measurement
of the concentration before and after the activation by
proteolytic cleavage of the leader peptide. Monitoring and
quantification of the active lantibiotic by integrating the
leader peptide peaks in RP-HPLC might be complicated due
to alteration of running properties of the pre-lantibiotics
and activated forms during the experiment and make it
difficult to distinguish between similar peaks. This strategy
has been used to determine the concentration of the activated
lantibiotic during the production of genome-mining new
lantibiotics as a hybrid containing the leader peptide of nisin
(Lagedroste et al., 2019).
Another important issue is incomplete modification of
target peptides such as lack of lanthionine ring formation
or the defected dehydrations of Ser/Thr residues which lead
to the disrupted recognition by the leader peptidases and
severe decline of their antimicrobial activities. Although MS
analysis of the cleavage products of pre-lantibiotics provides
useful information about the dehydration reaction by the
decrease of a water molecule mass (−18 Da), the technique
cannot indicate the formation of methyl-lanthionine rings. In
this regard, use of alkylation agents such as CDAP to bind
the free cysteine thiol or peptide digestion approach using
tandem MS-MS analysis to determine different patterns between
wild type and mutant variants has recently been introduced
(Kluskens et al., 2005). Verification of antimicrobial activity
of recombinant lantibiotics can also be conducted by growth
inhibition assay. Using lantibiotic-sensitive strains such as
L. lactis strain NZ9000, Listeria monocytogenes, Clostridioides
difficile, etc. have been reported in the literature (Field et al., 2010;
Cebrián et al., 2019).
Several techniques have been developed for verification and
quantification of nisin, such as turbidity assays (Berridge and
Barrett, 1952), colorimetric assays (Wang et al., 2007) and agar
diffusion bioassay (Mocquot and Lefebvre, 1956). Agar-based
bioassay, as the most widely used method for quantifying nisin
activity was implemented based on diffusion through agar gel
seeded with nisin-sensitive indicator bacteria (Pongtharangkul
and Demirci, 2004). The diameter of the inhibition zone
generated by growth inhibition of indicator bacteria is correlated
with the concentration of nisin. Factors such as nisin structure,
concentration of agar, pH, existence of detergent, number of
indicator cells and temperature can affect diffusion of nisin
through agar. Several researchers have attempted to improve
the accuracy, sensitivity, and reproducibility of conventional
agar diffusion bioassays for nisin by optimizing several factors
such as concentration of agar and buffering conditions, addition
of a detergent like Tween 20, incubation time adjustment,
and the temperature of pre-diffusion of the agar plates and
even the size of wells on agar (Rogers and Montville, 1991;
Wolf and Gibbons, 1996; Bonev et al., 2008; Lalpuria et al.,
2013).
A modified form of agar diffusion bioassay was established
upon activation of nisin by the membrane-associated protease
enzyme (NisP). Antimicrobial activity of precursor lantibiotics
and ncAA-modified variants synthesized by native producers
or heterologously expressed by host cells could be determined
using a sensitive indicator strain harboring appropriate
genes for the maturation of the lantibiotic. For example,
the nisin-sensitive indicator L. lactis NZ9000 pNZnisPT
pIL253 showed reasonable applicability to assess functional
and physicochemical properties of modified nisin variants
like proline, tryptophan, and lysine incorporated analogs
(Bartholomae et al., 2018). In addition, a bioactivity assay
for two-component lantibiotics such as lichenicidin which
requires the synergistic activity of two peptides was introduced
which is called “deferred antagonist bioassay.” Using agar
well diffusion plates by mixing the cell-free supernatants of
both separately producing strains in suitable proportions
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against growth of the indicator strain and the measurement
of inhibition radii after appropriate incubation at reasonable
temperature aid us to easily screen a large library of lantibiotic
mutants by avoiding time-consuming purification steps
(Barbosa et al., 2019).
Most Recent Advances in Recombinant
Lanthipeptides Production With an
Expanded Genetic Code
Bindman et al. (2015) have demonstrated that co-translational
backbone modification α-hydroxy acidic insertion works in
RiPPs in response to in-frame amber codons (SCS method).
They have shown the possibility of lantibiotic activation after
co-translational incorporation of α-hydroxy acids into the
precursor peptides in E. coli. The biosynthesis of lacticin
481 or nukacin ISK-1 analogs by incorporating Boc-HO-1,
HO-Phe(3-Br)-OH or HO-Tyr(propargyl)-OH at the junction
of the leader peptide to the core region of the lantibiotics
(position + 1) was successful. This enabled an improved
removal step of the leader peptide in a general manner
without the need to screen for various proteases (Bindman
et al., 2015). Efforts have also been reported to increase the
chemical diversity of lasso peptides and even to determine
the crystal structure of these complicated cyclic peptides in
the presence of bromine atoms (Piscotta et al., 2015). Sixteen
possible variants were expressed in E. coli at four positions
(Val6, Ile3, Phe10, Phe19). Thereby, four meta-substituted Phe
derivatives (m-ClPhe, m-BrPhe, m-NO2Phe and m-CF3Phe) were
incorporated into MccJ25 using an engineered “polyspecific”
MmPylRS. The results showed that the yield of ncAA-substituted
MccJ25 variants intensively depended on the position and the
chemical nature of the substitutions.
The use of ncAAs with 1,3- or 1,2-aminothiol reactive
groups to promote the cyclization of a downstream target
peptide sequence via a C-terminal ligation/ring contraction
mechanism has also been reported (Frost et al., 2015). It
has been demonstrated to be useful for the formation of
macrocyclic side-chain-to-tail peptides in vitro in a pH-
controlled manner. This strategy controls the spontaneous
cyclization of peptides of variable length and completely random
sequences with a wide range of molecular arrangements,
namely cyclic, lariat or C-terminal fused to a carrier protein
in living bacterial cells. The co-expression of glutamyl-
charged tRNAGlu in order to acylate specific Ser/Thr side
chains with glutamate prior to the dehydration reaction was
proposed by Zambaldo et al. (2017). The main intention
was to overcome an incomplete dehydration phenomenon
which occurs during incorporation of α-chloroacetamide-
containing ncAA to nisin variants having altered macrocyclic
topologies and antimicrobial activities. In an attempt to optimize
biophysical properties of cinnamycin from Streptococcus
albus for medical and industrial applications, three distinct
pyrrolysine analogs were incorporated into two distinct
positions of the antibiotic in Streptomycetes using the
orthogonal pyrrolysyl-tRNA synthetase/tRNAPyl pair from
Methanosarcina barkeri. In spite of a low rate of incorporation,
the data revealed that the type of ncAA and the position
of incorporation are important to achieve suitable amounts
of the new deoxycinnamycin derivatives (Lopatniuk et al.,
2017). Last but not least, the stereochemical configuration
of thioether bridges is an important issue, since recent
studies indicate that it is the property of the sequence of
the core peptide and not the modification enzyme that
determines the stereochemical outcome of ring formation
(Garg et al., 2016).
Although most of the reports regarding the site-specific
incorporation of ncAAs in RiPPs have shown lower levels of
antimicrobial activity of variants than the wild type, some
rare reports presented slightly improved activity on analogs
(Table 2). Notably, novel modified lantibiotic variants have
encrypted potential to show appropriate activity against newly
emerged pathogens.
CONCLUSION AND OUTLOOK
It has been estimated that 1.2 trillion USD are required
to cover additional health expenditure per year expected
by 2050 due to the rise of various AMRs (World Health
Organization, 2020). The World Health Organization (WHO)
has announced a global AMR response to coordinate this
in collaboration with international partners. According
to the WHO report on antimicrobial agents in clinical
development stages in 2019, the majority of antibacterial
agents are direct-acting small molecules (n = 108, 42.9%),
followed by non-traditional approaches (n = 90, 35.7%),
then AMPs (n = 27, 10.7%) as the main antibiotic agents
(World Health Organization, 2019). It was also argued that
the alarming rise in antibiotic resistance rates in the late
20th century is a clear indication that the golden age of
antibiotics might be over (Wernicki, 2013). All these figures
and projections urge us to reconsider current approaches and
anticipate possible future paths to alternatives. In many cases,
superbugs are characterized by increased multi-drug resistance,
improved transmissibility and virulence, resulting in increased
morbidity and mortality.
Multi-drug resistance in bacteria is a very complex problem,
deeply rooted in the genetic and biochemical flexibility of
bacteria, i.e., a highly pleiotropic phenomenon. Obviously, this
problem cannot be solved only by simple solutions such as
chemical modifications or variations of known lead substances.
Therefore, we believe that the time is coming to use more
extensively the most advanced methods of Synthetic Biology
such as expanded genetic code to combat superbugs that have
continuously evolved in most industrialized nations over the
last 60 years. Here we attempted to summarize the efforts
that have been made by the help of expanded genetic code to
introduce new-to-nature lanthipeptides as promising alternatives
to classical chemical agents. We have also tried to present new
insights and progress in the field as well as the limitations and
challenges which should be overcome in the future. We are firmly
convinced that “radical" methods of genetic engineering (Davies
and Church, 2019), such as the expansion of the genetic code, can
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be a useful addition to the struggle against superbugs as a global
threat to all of mankind.
In the present medical context and in the current environment
of failing antibiotic protection, an obvious functional expansion
is a fortification against post-surgery antibiotic infections, for
example by coupling therapeutic proteins to antimicrobial
modules. New approaches such as genetically encoded chemical
conversion (GECCO) has also been recently introduced (Yang
et al., 2019) to overcome limitations of translational machinery.
This and other newly emerged approaches such as OTS
optimization (Dulic et al., 2018), cell-free protein synthesis (Jin
and Hong, 2018), genomically recorded strain development
(Amiram et al., 2015), artificial codon box division (Iwane
et al., 2016), and quadruplet codon and orthogonal ribosome
(d’Aquino et al., 2018) are expected to open new avenues
for exploiting chemistry in live systems to bioengineering of
lanthipeptides. GCE as a research field has now reached the
maturity to be efficiently implemented in the bioengineering
of lanthipeptides to understand their structural complexity
and the behavior of the entire biosynthesis machinery. This
should provide a solid basis for expanding the chemical space
of recombinant AMPs. The aim is not only improving their
therapeutic properties to combat AMR but also to repurpose
them functionally for, e.g., anticancer or antiviral activities.
The application of co-translational incorporation of ncAAs by
more than 200 different chemical entities available to us for
rational manipulation of various scaffolds offers unprecedented
opportunities to manage the supply of advanced peptide-based
antimicrobials and other sophisticated drugs in the future.
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